Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: About the safety and how well people tolerate of patritumab deruxtecan How many people have the cancer respond (get smaller or go away) to treatment
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Neoplasms
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz Medical Campus ( Site 0057) · Aurora, CO
Massachusetts · 1
- Dana-Farber Cancer Institute ( Site 0050) · Boston, MA
New Jersey · 1
- Rutgers Cancer Institute of New Jersey ( Site 0052) · New Brunswick, NJ
South Carolina · 1
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) · Greenville, SC
Virginia · 1
- Inova Schar Cancer Institute ( Site 0051) · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.